Category: Tysabri

Orphan Drug Designation Granted to Treatment for Rare Multiple Sclerosis Drug Complication

The Food and Drug Administration granted Orphan Drug Designation to Inhibikase Therapeutics’, Inc. lead product, IkT-001Pro (imatinib), to treat progressive multifocal leukoencephalopathy(PML). According…

Stuart Schlossman

Rare Brain Infection Death Spurs FDA To Update Warning Label for MS Drug

Posted by: Anna Tan, RN November 26, 2014 The US Food and Drug Administration has just issued a report warning the general public and…

Stuart Schlossman

Smoking Ups Natalizumab Neutralizing Antibodies in MS

Sue Hughes –  October 03, 2014 BOSTON — Smoking appears to increase the likelihood of developing neutralizing antibodies to natalizumab (Tysabri, Biogen Idec),…

Stuart Schlossman

Multiple Sclerosis Symptom Recrudescence at the End of the Natalizumab Dosing Cycle

Volume 16, Issue 2 (Summer (2014) Article Citation:John N. Ratchford, Regina Brock-Simmons, Amanda Augsburger, Sonya U. Steele, Kristie Mohn, Mandi Rhone,…

Stuart Schlossman

Tysabri Protects Against Relapse in Multiple Sclerosis, According To Study

According to a study published in JAMA Neurology, multiple sclerosis patients are greatly benefited by Biogen Idec’s Tysabri (natalizumab) and tend to relapse…

Stuart Schlossman

To Stay, or Not to Stay, on Natalizumab in MS

Pauline Anderson June 02, 2014 DALLAS — Switching to fingolimod (Gilenya, Novartis) or an injectable therapy after 2 years of treatment with…

Stuart Schlossman

Biogen Idec Investigates Tysabri in Secondary-Progressive Multiple Sclerosis Patients

Biogen Idec is currently sponsoring a clinical trial evaluating its therapy Tysabri (natalizumab) in patients with secondary-progressive multiple sclerosis. Although relapse-remitting multiple…

Stuart Schlossman

Inhibikase Therapeutics Receives Orphan Drug Designation for treatment of Progressive Multifocal Leukoencephalopathy (PML)

ATLANTA, May21, 2014 /PRNewswire/ –Inhibikase Therapeutics, Inc., an emerging developer of products to treat infectious diseases with little or no resistance, announces…

Stuart Schlossman

Multiple Sclerosis Symptom Recrudescence (feeling cruddy) Is Common at the End of the Natalizumab Dosing Cycle

Source: International Journal of MS Care Article Citation:John N. Ratchford, Regina Brock-Simmons, Amanda Augsburger, Sonya U. Steele, Kristie Mohn, Mandi…

Stuart Schlossman

New TYSABRI® Analysis at AAN Annual Meeting Shows Improved Walking Speed in Significant Number of MS Patients

New TYSABRI® Analysis at AAN Annual Meeting  Shows  Improved Walking Speed in Significant Number  of MS Patients Biogen Idec (BIIB) today…

Stuart Schlossman

Categories

Latest Blog Posts